Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001724521-24-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-04 | 2024-01-02 | RCUS | Goeltz II Robert C. | CFO | S - Sale | $20.00 | -2,004 | 51.8K | -4% | -$40.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | S | D | 2,004 | $20.00 | 51,831 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023. |